T100: Long term Follow‐up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG‐ACRIN Research Group (E4412: Arms A‐I) | Zendy

Diefenbach Catherine | Zendy; Jegede Opeyemi | Zendy; Ambinder Richard | Zendy; Cohen Jonathon | Zendy; Robertson Michael | Zendy; David Kevin | Zendy; Advani Ranjana | Zendy; Fenske Timothy | Zendy; Barta Stefan | Zendy; Palmisiano Neil | Zendy; Svoboda Jakub | Zendy; Morgan David | Zendy; Karmali Reem | Zendy; Kahl Brad | Zendy; Ansell Stephen M. | Zendy

Open Access

T100: Long term Follow‐up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG‐ACRIN Research Group (E4412: Arms A‐I)

Author(s) -

Diefenbach Catherine,

Jegede Opeyemi,

Ambinder Richard,

Cohen Jonathon,

Robertson Michael,

David Kevin,

Advani Ranjana,

Fenske Timothy,

Barta Stefan,

Palmisiano Neil,

Svoboda Jakub,

Morgan David,

Karmali Reem,

Kahl Brad,

Ansell Stephen M.

Publication year - 2022

Publication title -

hemasphere

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.677

H-Index - 11

ISSN - 2572-9241

DOI - 10.1097/01.hs9.0000890968.53519.f4

Subject(s) - medicine , brentuximab vedotin , rash , nivolumab , ipilimumab , nausea , gastroenterology , adverse effect , pneumonitis , surgery , oncology , lymphoma , cancer , lung , immunotherapy , hodgkin lymphoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog